Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-09-25

FDA Approved: TAGRISSO — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for Tagrisso (osimertinib) from AstraZeneca Pharmaceuticals LP. This action updates the labeling and/or indication f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TAGRISSO (osimertinib)

Snippet

SUPPL AP for TAGRISSO (OSIMERTINIB)